ERBB2 and cancer: Seven candidate peptides of consensus sequence WxxGxAxGS were tested in vivo and two were classified as optimal candidates based on (i) capacity to induce an Ab response, (ii) specificity of the induced Abs, and (iii) capacity to inhibit proliferation when applied to HER2-overexpressing cancer cells.